India In Vitro Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

India’s IVD landscape is moving towards decentralised molecular testing that can deliver results closer to patients rather than relying entirely on central laboratories. This is particularly relevant for infectious diseases where rapid diagnosis can influence treatment decisions and surveillance. The regulatory ecosystem is also supporting rapid diagnostic development, with CDSCO maintaining guidance for rapid pathogen identification and antimicrobial susceptibility testing. Molbio Diagnostics’ Truenat platform illustrates this shift through portable molecular testing capabilities designed for use beyond conventional laboratory settings. The growing emphasis on affordable, deployable molecular systems is creating opportunities for manufacturers developing compact analysers, cartridge-based assays and multiplex testing platforms for hospitals, primary healthcare facilities and other decentralised settings.

Artificial intelligence is increasingly being incorporated into Indian IVD technologies, particularly for image analysis, pathology and molecular interpretation. In February 2026, the Technology Development Board supported Ayukriyam Innovations for development of Autoscope, an automated whole-slide imaging system integrating AI-driven diagnostics. The platform is intended to support rapid diagnosis of infectious diseases, including in resource-constrained settings. AI integration is therefore moving beyond experimental applications towards diagnostic systems that can automate image interpretation and assist laboratory professionals. This trend is encouraging IVD companies to combine imaging hardware, software and machine-learning models, while also increasing demand for validated algorithms capable of improving consistency and processing large volumes of diagnostic data.

Domestic production of IVD technologies is becoming increasingly important as Indian manufacturers develop capabilities across diagnostic kits, reagents and molecular testing platforms. In March 2026, the Technology Development Board provided financial assistance to Chennai-based Acrannolife Genomics for an advanced manufacturing facility supporting its Trunome GrafAssure and TBFYND IVD kits. The technologies use cell-free DNA and LAMP-based platforms for applications including infectious disease and transplant diagnostics. Such initiatives indicate a shift from dependence on imported diagnostic technologies towards locally developed and manufactured products. The trend is also creating opportunities for Indian companies to combine indigenous R&D with scalable manufacturing and potentially expand their presence in international diagnostic markets.

IVD manufacturers in India are facing a progressively more structured performance evaluation environment. ICMR and CDSCO have developed standard performance evaluation protocols covering specific diagnostic technologies and infectious disease assays. CDSCO also maintains designated laboratories for IVD performance evaluation and updated the list of such laboratories in June 2026. In July 2026, CDSCO invited comments on a draft standard evaluation protocol for scrub typhus diagnostics. This increasing standardisation is encouraging manufacturers to generate more consistent analytical and clinical performance evidence before commercialisation. It is also creating demand for laboratories with specialised validation capabilities and encouraging IVD developers to incorporate regulatory and performance requirements earlier into product development.

The Indian IVD market is increasingly extending into advanced molecular, genomic and non-invasive diagnostic technologies rather than remaining concentrated around conventional biochemical and immunoassay testing. Acrannolife Genomics is developing cell-free DNA and LAMP-based IVD technologies for infectious disease and transplant applications, while AI-enabled whole-slide imaging is being developed for automated diagnostic interpretation. At the regulatory level, CDSCO has also introduced dedicated guidance covering IVD software, stability studies and performance evaluation. Together, these developments indicate growing demand for molecular diagnostics, digital pathology, genomic testing and software-enabled IVD systems. This diversification is broadening the addressable applications for Indian diagnostic manufacturers across infectious diseases, oncology, transplantation and precision healthcare.